Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: An exploratory study

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1237-1246

  Liu, Dongxin ^a   O'Day, Steven J ^b   Yang, Dongyun ^a   Boasberg, Peter ^b   Milford, Robert ^b   Kristedja, Tim ^b   Groshen, Susan ^a   Weber, Jeffrey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTOKINE; DACARBAZINE; GAMMA INTERFERON; GENOMIC DNA; INTERLEUKIN 10; INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CODON; DNA POLYMORPHISM; DNA REPAIR; FEMALE; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; X RAY; XERODERMA PIGMENTOSUM;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DNA HELICASES; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 12944291453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
2. McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma. Clin Cancer Res 2000;6:2201-8.
3. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-61.
4. Rossen RD, Crane MM, Morgan AC, et al. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer Res 1983;43:422-9.
5. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
6. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991;97:197-202.
7. Nathanson L. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 1976;44:67-76.
8. Halloran PF. Interferon-γ, prototype of the proinflammatory cytokines - importance in activation, suppression, and maintenance of the immune response. Transplant Proc 1993;25:10-5.
9. Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL. Immunomodulatory function of interferon-γ in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. J Immunother 1997;20:146-57.
10. Anichini A, Mortarini R, Fossati G, Parmiani G. Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ. Int J Cancer 1986;38:505-11.
11. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur J Immunogenet 1999;26:1-3.
12. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ production. Hum Immunol 2000;61:863-6.
13. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994;1:173-85.
14. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
15. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2:1383-90.
16. Fonts C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996;104:1-5.
17. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001;19:239-47.
18. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001;60:2385-91.
19. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980;30:151-69.
20. Graham GM, Guarini L, Moulton TA, et al. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunol Immunother 1991;32:382-90.
21. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-6.
22. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075-9.
23. Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8.
24. Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW. Human DNA repair systems: an overview. Environ Mol Mutagen 1999;33:3-20.
25. Wilson MD, Ruttan CC, Koop BF, Glickman BW. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001;38:209-15.
26. Gaillard PH, Wood RD. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res 2001;29:872-9.
27. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555-60.
28. Masson M, Niedergang C, Schreiber V, Muller S, de Murcia JM, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71.
29. Lunn R, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-61.
30. Duell E, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-71.
31. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash L. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-5.
32. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms. Transpl Immunol 1999;7:127-8.
33. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
34. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989;8:771-83.
35. Chen CH, George SL. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 1985;4:39-46.
36. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-93.
37. Park JY, Park SH, Choi JE, et al. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:993-7.
38. Xing D, Tan W, Wei Q, Lin D. Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 2002;38:123-9.
39. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-54.
40. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
41. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
42. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon α. Hepatology 1999;30:526-30.
43. Meyskens FL Jr, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon γ versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995;87:1710-3.
44. Porter GA, Abdalla J, Lu M, et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001;8:116-22.
45. Lee JE, Abdalla J, Porter GA, et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients. Ann Surg Oncol 2002;9:587-93.
46. Anichini A, Mortarini R, Fossati G, Parmiani G. Phenotypic profiles of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon. Int J Cancer 1986;38:505-11.
47. Anichini A, Castelli C, Sozzi G, Fossati G, Parmiani G. Differential susceptibility to recombinant interferon-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J Immunol 1988;140:183-91.
48. Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer 1989;44:554-9.
49. Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984;82:244-7.
50. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988;41:562-7.
51. Taramelli D, Fossati G, Balsari A, Marolda R, Parmiani G. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer 1984;34:797-806.
52. + melanoma. Int Immunol 1993;5:1501-8.
53. Le Poole IC, Riker AI, Quevedo ME, et al. Interferon-γ reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002;160:521-8.